Products & Services
Company Description
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.
Business Contact Information
- Phone
- +1 (650) 9004520
- Fax
- No data
- Website
- www.corvuspharma.com
- No data
- Address
- 863 Mitten Rd, Burlingame, California, 94010, United States
Industry & Classification
- Industry Name Level 1
- Industrial & mechanical
- Industry Name Level 2
- Machinery
- Industry Name Level 3
- Industrial machinery
NAICS Codes
- 32
- 3254
- 325412
SIC Codes
- 28
- 283
- 2834
Company Details
- Employees
- 31 (21-50)
- Annual Revenue
- $5M-$10M
- Established
- No data
- Total Funding
- No data
- Latest Funding
- No data
Own this business?
Keep your profile accurate — or ask us to take it down. We acknowledge requests within 7 days and resolve them within 30 days.
Prefer email? privacy@facturmfg.com